M. Maurer, K. Bork, I. Martínez-Saguer
Oct 23, 2018
Citations
1
Influential Citations
8
Citations
Journal
Journal of the European Academy of Dermatology and Venereology
Abstract
The Icatibant Outcome Survey (IOS; NCT01034969) is a Shire‐sponsored, international, observational study monitoring the safety and effectiveness of icatibant, a bradykinin B2 receptor antagonist approved for the acute treatment of adults with hereditary angioedema with C1 inhibitor deficiency (HAE‐C1‐INH).